Ayahuasca and Antidepressants: What the Research Actually Shows

This is the most common medical question in the ayahuasca world, and it gets answered badly in two opposite directions.

One answer is alarmist: mixing them will kill you. The other is careless: stop your SSRI a week before and you’ll be fine. The first discourages people from asking honestly. The second is the one that actually hurts people — not usually through serotonin syndrome, but because abruptly stopping an antidepressant to make a retreat date is a genuinely dangerous thing to do to yourself.

The real picture sits in between, and it’s more interesting than either.

Ayahuasca and antidepressants interact through two separate mechanisms, only one of which gets discussed. The evidence base is thinner than most centres imply. And the most important safety decision in the whole business isn’t about the brew at all — it’s about who supervises the medication change, and how far in advance.

Our related pages on ayahuasca risks and who should not drink ayahuasca cover contraindications broadly. This one goes deep on the interaction that matters most.

The Short Answer

• Ayahuasca contains reversible MAO-A inhibitors. SSRIs block serotonin reuptake. Together they can push serotonin activity too high.
• Serotonin syndrome is the named risk. It runs from mild and self-limiting to, rarely, fatal — and MAOI combinations produce the most severe cases.
• There’s a second interaction almost nobody mentions: some SSRIs inhibit the liver enzyme that clears ayahuasca’s alkaloids, which recent modelling suggests roughly doubles DMT exposure.
• The published evidence is limited — case reports and pharmacological modelling, not large controlled trials. Thin data is not the same as safety.
• Stopping your antidepressant is also a risk, and a serious one. That decision belongs to your prescriber, planned months ahead.
• Reputable centres, including ours, decline participants on this basis. That’s the system working.

Why Ayahuasca Is Pharmacologically Unusual

Most psychedelics are one active compound. Ayahuasca is a partnership between two plants, and understanding why matters here.

Chacruna (Psychotria viridis) supplies DMT. Taken orally on its own, DMT does essentially nothing — enzymes in the gut and liver, principally monoamine oxidase A, break it down before it reaches the brain.

The caapi vine (Banisteriopsis caapi) supplies harmala alkaloids: harmine, harmaline and tetrahydroharmine. These inhibit MAO-A. With that enzyme suppressed, the DMT survives digestion and becomes orally active.

So the brew works because it contains an MAO inhibitor. That isn’t an impurity or a side effect. It’s the mechanism.

Two refinements that matter:

The inhibition is reversible. Harmala alkaloids are reversible inhibitors of MAO-A — RIMAs — which behave very differently from irreversible pharmaceutical MAOIs like phenelzine, where the enzyme has to be regenerated over weeks. Reversible inhibition wears off far faster. This is why ayahuasca’s dietary restrictions are measured in days rather than the weeks a psychiatric MAOI requires.

Tetrahydroharmine does something extra. THH is itself a weak serotonin reuptake inhibitor. So the brew doesn’t only remove the enzyme that breaks serotonin down — it also mildly blocks reuptake, in the same direction an SSRI works. The serotonergic load comes from more than one place at once.

How Ayahuasca and Antidepressants Collide

Pathway one: too much serotonin

An SSRI keeps serotonin in the synapse by blocking its reuptake. An MAO-A inhibitor stops serotonin being broken down. Add a compound that mildly blocks reuptake as well, and you have three mechanisms pushing in one direction with nothing pushing back.

This is textbook. MAOI plus SSRI is one of the classic contraindicated combinations in clinical medicine, and it has been for decades.

Pathway two: the liver enzyme nobody mentions

Here’s the part that rarely appears in retreat literature, and it’s the most concrete evidence available.

A 2026 study in Frontiers in Molecular Biosciences built physiologically based pharmacokinetic models of what happens when ayahuasca alkaloids meet SSRIs. The finding is specific:

• Fluoxetine increased harmine exposure by around 1.26–1.28× and DMT exposure by 2.1–2.2×
• Paroxetine increased harmine by around 1.20–1.25× and DMT by 2.11–2.16×

The mechanism is indirect and rather elegant. Both drugs inhibit CYP2D6, a liver enzyme that clears harmine. Less clearance means more harmine. More harmine means deeper MAO-A inhibition. Deeper inhibition means more DMT survives — roughly double.

The authors conclude that co-administration of potent CYP2D6 inhibitors “may result in clinically relevant increases in systemic exposure to HRM and moderate increases in DMT exposure, potentially elevating the risk of serotonergic effects.”

Read plainly: an SSRI doesn’t only add serotonin to the equation. It also makes the same cup of ayahuasca substantially stronger than the person serving it intends.

The authors are appropriately careful about limits — human pharmacokinetic data for DMT and harmine remain scarce, and there’s no established relationship between DMT brain concentration and toxic outcomes. This is modelling, not observation. But it is the best mechanistic evidence available, and it points one way.

Diagram of the two interaction pathways between ayahuasca and antidepressants Alt text: The two interaction pathways between ayahuasca and antidepressants — serotonergic load and CYP2D6 inhibition

Serotonin Syndrome, Described Accurately

Neither a myth nor an inevitability. Here is what it actually is.

Serotonin syndrome is excessive serotonergic activity in the central nervous system, arising when something inhibits reuptake, blocks metabolism, or over-activates receptors — or several at once.

Clinicians recognise it through a triad: altered mental status (agitation, confusion, delirium), autonomic instability (fast heart rate, high blood pressure, fever, sweating), and neuromuscular excitation (tremor, hyperreflexia, and clonus — involuntary rhythmic muscle contractions, typically most pronounced in the legs).

The Hunter Toxicity Criteria are the diagnostic standard, requiring recent exposure to a serotonergic agent plus at least one of: spontaneous clonus; inducible clonus with agitation or sweating; ocular clonus with agitation and sweating; tremor with hyperreflexia; or rigidity with fever above 38°C plus clonus. Against expert toxicologist assessment these criteria run at 84% sensitivity and 97% specificity.

Onset is typically within 6 to 24 hours of the triggering exposure.

Severity spans a wide range. Many cases are mild and resolve with observation and withdrawal of the offending agent. Severe cases require intensive care, and can involve seizures, rhabdomyolysis and disseminated intravascular coagulation. Deaths occur but are uncommon.

And the relevant detail here: MAOI-containing combinations tend to produce the most severe presentations. That’s precisely the category ayahuasca falls into.

Note also how badly this maps onto a ceremony. Agitation, confusion, sweating, tremor, racing heart and high temperature are all things a facilitator might reasonably attribute to an intense ayahuasca experience. In a maloca at night, in the dark, the early signs of a serious drug interaction look a great deal like an ordinary difficult journey.

What the Evidence Does and Doesn’t Show

Honesty here is more useful than confidence.

There are no large controlled trials of ayahuasca in people taking SSRIs, and there won’t be — you cannot ethically design that study.

The clinical literature is thin. Psychiatrist Charles Grob, one of the few researchers to have published on ayahuasca’s adverse effects, has pointed out that his own widely cited work rests on a handful of case reports from 1998 — patients who experienced significant distress, confusion, agitation, raised temperature and muscular rigidity, and who all recovered. He has been explicit that formal studies are designed to exclude the people most at risk, so systematic interaction data simply doesn’t exist.

The pharmacology is not thin. The mechanism is well characterised, the MAOI-SSRI contraindication is long established in medicine, and the PBPK modelling gives concrete numbers.

What follows from that: the absence of a body count is not evidence of safety. It reflects the fact that most retreat centres screen these participants out, that adverse events in the Amazon are not systematically reported to anyone, and that no registry exists.

Anyone who tells you it’s fine because “people do it all the time” is reasoning from an absence of data collection.

The Question Underneath: “But Isn’t Ayahuasca Meant to Treat Depression?”

Most people asking about SSRIs are asking for a reason. They’re on an antidepressant because they have depression, they’ve read that ayahuasca helps with depression, and the medication has become the obstacle between them and the thing that might work.

That reasoning deserves a straight answer rather than a marketing one.

• Ayahuasca is not a treatment for depression. It is not approved as one anywhere, we do not offer it as one, and it would be irresponsible of us to imply otherwise. Our ayahuasca ceremony is a traditional Andean ceremonial practice, described in experiential and cultural terms — which is the only honest framing available to us.
• The research is genuinely interesting and genuinely preliminary. There is early clinical work on ayahuasca and treatment-resistant depression, and it has produced results that have made serious researchers pay attention. That is a long way from an established therapy. Small samples, short follow-up, and — critically — trials conducted with medical screening, controlled dosing and clinical monitoring that a retreat in the Andes does not replicate.
• And note the circularity. Those trials exclude people on serotonergic medication for exactly the reasons this article describes. The evidence people cite when they want to come off their SSRI to drink ayahuasca was generated in people who were already off it, under supervision, as part of a study protocol.
• The hardest version of this. If you are currently unwell, currently medicated, and hoping a ceremony will do what the medication hasn’t — that is the situation in which stopping the medication is most dangerous and the ceremony least likely to be held safely. It’s also the situation in which people are most tempted to conceal things at screening.

If that’s where you are, the most useful thing on this page is the sentence at the top: talk to a doctor. Not instead of the Andes. Before them.

The Medications That Matter

Not exhaustive. Disclose everything you take, including things you don’t think of as medication.

Class	Examples	Concern
SSRIs	Fluoxetine, sertraline, paroxetine, citalopram, escitalopram	Serotonin syndrome; several also inhibit CYP2D6
SNRIs	Venlafaxine, duloxetine	Serotonin syndrome
Tricyclics	Amitriptyline, clomipramine	Serotonin syndrome; cardiac effects
MAOIs	Phenelzine, tranylcypromine, moclobemide	Highest risk category. Irreversible MAOIs require weeks to clear
Lithium	—	Classic psychedelics co-administered with lithium have been associated with seizures. Treated as an absolute exclusion
Tramadol	—	Both serotonergic and seizure-lowering
Triptans	Sumatriptan and others	Serotonergic
St John’s Wort	—	Herbal, widely assumed harmless, genuinely serotonergic
Stimulants	Amphetamine, methylphenidate	Sympathomimetic load on top of MAO inhibition
Dextromethorphan	In many cough remedies	Serotonergic; easily overlooked
Decongestants	Pseudoephedrine and similar	Sympathomimetic; hypertensive risk with MAOI

Lithium deserves its own line. Beyond the serotonergic question, analyses of psychedelic experience reports and individual case reports have linked lithium co-administration with classic psychedelics to seizures. No reputable centre accepts a participant on lithium. Neither do we.

The Part Everyone Gets Wrong: Stopping Is Also Dangerous

If this article changes one thing, let it be this.

The conversation is almost always framed as “how long before the retreat do I need to be off it?” — as though the only question were clearing the drug in time. That framing has the risk backwards.

Antidepressant discontinuation carries real harm. Stopping abruptly can produce discontinuation symptoms: dizziness, electric-shock sensations, nausea, insomnia, irritability, flu-like malaise. More importantly it carries a risk of relapse of the underlying condition — and for some people, relapse means returning to a very dark place, potentially thousands of miles from home, in an unfamiliar country, at altitude, about to undertake something psychologically demanding.

Half-lives vary enormously. Fluoxetine and its active metabolite persist far longer than most; Grob has suggested four to five weeks for it to fully clear, while other agents are shorter. This is exactly why a single blanket “stop two weeks before” rule is not clinically meaningful.

Which brings us to the non-negotiable.

This article does not, and will not, tell you how or when to taper. No retreat centre should. That decision belongs to the doctor who prescribed the medication, made with knowledge of your history, your diagnosis, your dose, your relapse risk, and what has happened when you’ve stopped before.

If a centre gives you a tapering schedule, that is not a service. It is a company with a commercial interest in your attendance making a clinical decision it is not qualified to make.

Plan in months, not weeks. A supervised, safe reduction — where one is appropriate at all — takes time, and your prescriber may reasonably conclude it isn’t appropriate. That is a legitimate outcome, not an obstacle to be worked around.

Our Screening Policy, Stated Plainly

We would rather publish this than have you discover it at the point of booking.

• Everyone completes a health questionnaire before we accept payment. It asks for all medications and supplements, doses, how long you’ve been taking them, and your medical and psychiatric history — yours and your immediate family’s.
• We ask about the things people forget: over-the-counter cough remedies, migraine medication, herbal supplements, weight-loss products, recreational substances.
• We follow up on ambiguous answers rather than taking the most convenient reading.
• We decline people. For current serotonergic medication where discontinuation hasn’t been properly supervised and completed. For lithium. For cardiac conditions and uncontrolled hypertension. For epilepsy. For a personal or family history of psychosis, schizophrenia or bipolar disorder. For pregnancy and breastfeeding.
• We ask for evidence of prescriber involvement where a medication change is part of the picture. Not a note from you saying you stopped — confirmation that the person who prescribed it was part of the decision.
• Please do not conceal a medication. People do, because they’ve travelled a long way and are afraid of being turned away, and it is the single most dangerous thing you can do in this context. Tell us. There is often a workable path, and it always starts with the truth.
• And if we decline you, it isn’t a judgement. Our ayahuasca retreat safety protocols and preparation guidance set out the rest of the process.

If You’re on Antidepressants and Want to Do This

A realistic path, in order.

1. Talk to your prescriber first — before booking anything. Not after paying a deposit. Their answer shapes everything, including whether the trip happens.
2. Accept that the answer may be no, or not yet. For some people, stopping is straightforwardly unwise. A retreat is not worth a relapse.
3. If a reduction is agreed, plan it around your life, not your flights. Under supervision, with time to see how you respond, and with a plan for what happens if you don’t respond well.
4. Tell the centre everything. Including the history, not just the current state.
5. Consider going anyway, and doing something else. This is the option nobody offers, and it’s a real one.

A coca leaf reading and a Pachamama offering carry no pharmacological contraindications whatsoever. Neither is psychoactive. Both are genuine Andean ceremonies with real depth, and people frequently describe them as the most affecting part of their journey regardless of what else they did.

Coming to the Andes and not drinking ayahuasca is not a failed trip. Our full range of ceremonies is a good place to look at what else the tradition holds.

• And if you still want to drink, come back when it’s safe to. The mountains keep.

Warning Signs During a Ceremony

For facilitators and participants both, because these can be mistaken for an intense journey.

Escalating agitation and confusion beyond the usual arc. Muscle rigidity or tremor. Involuntary rhythmic jerking, especially in the legs. Skin hot to the touch. Heavy sweating with a racing pulse. Rapidly rising body temperature.

Any combination of those, particularly in someone who has recently stopped or is still taking a serotonergic medication, needs medical attention rather than more support in the maloca. Onset typically falls within six to twenty-four hours of exposure.

This is one reason to ask a centre a very concrete question before you book: what happens medically if something goes wrong, and how far is the nearest hospital?

Frequently Asked Questions

Why We Published This

Most retreat centres bury this in a FAQ, and a few give tapering advice they have no business giving.

We’d rather put it at the front. Partly because it’s the right thing to do, and partly for a plainer reason: if you’re reading this and deciding not to come this year, that’s a better outcome for both of us than you arriving in Chinchero with something undisclosed.

The medicine has been here a long time. It’ll still be here when your doctor says the timing is right.

If you want to talk it through before booking anything, ask us — including if the answer might be that this isn’t your year. And if the reason you’re drawn to ayahuasca is that you’re struggling and nothing else has worked, please talk to a doctor or someone you trust as well. That conversation matters more than the retreat, and we’d rather say so.

This article summarises publicly available research for general information and is not medical advice. It does not create a clinical relationship and must not be used to alter prescribed medication. Ayahuasca is not a treatment for any medical or psychiatric condition. Participation in any ceremony requires honest health disclosure and is undertaken on the basis of informed personal responsibility. Sources: Frontiers in Molecular Biosciences; StatPearls, NCBI Bookshelf; PubMed; medical guidelines published by Temple of the Way of Light.